Skip to Main Content

Paper Details

Cisplatin Resistance in Osteosarcoma: <i>In vitro</i> Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.
Front Oncol
26
2020
CDDP, Cisplatin, FGFR, MAPK, NER factors, NERI02, NSC130813, Osteosarcoma, cisplatin, cisplatin-resistant variants, fibroblast growth factor receptor, genes, high-grade osteosarcoma, human, human osteosarcoma cell lines, human osteosarcoma cells, malignant tumor of bone, mitogen-activated protein kinase, nucleotide, osteosarcoma, parental cell lines, patients, triptolide
Author NameAffiliation
Claudia Maria HattingerIRCCS Istituto Ortopedico Rizzoli, Pharmacogenomics and Pharmacogenetics Research Unit
Claudia Maria HattingerIRCCS Istituto Ortopedico Rizzoli, Pharmacogenomics and Pharmacogenetics Research Unit
Massimo SerraIRCCS Istituto Ortopedico Rizzoli, Pharmacogenomics and Pharmacogenetics Research Unit
Massimo SerraIRCCS Istituto Ortopedico Rizzoli, Pharmacogenomics and Pharmacogenetics Research Unit
  • 1 - 4

Datasets

Release 1.2